Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation (PERSIST-END IDE)

NCT03650556 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.

NCT NCT03650556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03650556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation (PERSIST-END IDE)
Lead sponsor
Abbott Medical Devices
Phase
Not applicable
Overall status
Completed
Start date
September 28, 2018
Completion date
January 11, 2021
Enrollment
224 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation